LENZ Therapeutics (NASDAQ:LENZ) Raised to “Hold” at Zacks Research

LENZ Therapeutics (NASDAQ:LENZ) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other research firms have also recently weighed in on LENZ. Piper Sandler reduced their price objective on LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Finally, Weiss Ratings downgraded LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LENZ Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.80.

LENZ Therapeutics Trading Up 2.8%

LENZ opened at $4.73 on Thursday. The stock has a market capitalization of $148.62 million, a P/E ratio of -1.16 and a beta of 0.65. LENZ Therapeutics has a 12 month low of $4.53 and a 12 month high of $50.40. The firm’s fifty day simple moving average is $5.64 and its 200 day simple moving average is $9.01.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.03. LENZ Therapeutics had a negative return on equity of 53.39% and a negative net margin of 586.74%.The firm had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $2.38 million. On average, equities research analysts predict that LENZ Therapeutics will post -4.18 EPS for the current fiscal year.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $27,000. Osaic Holdings Inc. raised its position in LENZ Therapeutics by 2,146.2% during the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after acquiring an additional 1,116 shares in the last quarter. Tower Research Capital LLC TRC raised its position in LENZ Therapeutics by 51.4% during the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after acquiring an additional 477 shares in the last quarter. State of Wyoming acquired a new stake in LENZ Therapeutics in the fourth quarter valued at $30,000. Finally, BNP Paribas Financial Markets lifted its stake in LENZ Therapeutics by 93.7% in the second quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 944 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

More LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: LENZ’s VIZZ prescriptions reportedly increased more than 45% month over month in July, while the company outlined telehealth and national television initiatives intended to support broader product adoption. Lenz outlines July telehealth and national TV push as VIZZ scripts rise over 45% month over month
• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its Q3 2026 EPS forecast to a loss of $1.02 from a loss of $1.15. It also improved its FY2026 estimate to a loss of $4.35 from a loss of $4.74, suggesting somewhat better near-term expectations.
• Neutral Sentiment: The company’s Q2 2026 earnings call focused on VIZZ’s launch progress and commercialization efforts, giving investors additional information about early demand and the strategy for expanding the product’s reach. LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
• Negative Sentiment: Bank of America downgraded LENZ on concerns that VIZZ’s launch may be slower than expected, a significant issue for a company whose valuation depends on successful commercial execution. Lenz drops as BofA downgrades on a slower VIZZ launch
• Negative Sentiment: HC Wainwright reduced its longer-term EPS forecasts for FY2027 through FY2029 and sharply cut FY2030 EPS to $0.63 from $2.72. Although the firm remains bullish, the revisions imply a slower path to profitability and weigh on the stock’s long-term outlook.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.